Key Points
- Director Kapil Dhingra sold 3,169 shares of Replimune on Dec. 9 at an average price of $10.40 for a total of $32,957.60, according to an SEC filing.
- REPL traded up 1.0% to $9.97 on Friday with 89,040 shares changing hands (vs. average volume ~4.2M); the stock has a 52‑week range of $2.68–$14.80 and a market cap of about $782 million with a negative P/E.
- Analysts are mixed but tilted positive—average rating " Moderate Buy" with a $9.75 target after several upgrades—while institutions/hedge funds own roughly 92.53% of the stock.
Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) Director Kapil Dhingra sold 3,169 shares of Replimune Group stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total value of $32,957.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Replimune Group Trading Up 1.0%
REPL traded up $0.10 during trading on Friday, hitting $9.97. 89,040 shares of the company's stock were exchanged, compared to its average volume of 4,205,552. Replimune Group, Inc. has a 1 year low of $2.68 and a 1 year high of $14.80. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26. The firm has a market cap of $781.97 million, a P/E ratio of -2.88 and a beta of 0.66. The stock has a 50 day moving average price of $8.35 and a 200 day moving average price of $7.61.
Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.03). As a group, analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. US Bancorp DE boosted its stake in Replimune Group by 582.6% in the 1st quarter. US Bancorp DE now owns 4,594 shares of the company's stock worth $45,000 after purchasing an additional 3,921 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company's stock worth $64,000 after buying an additional 1,879 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Replimune Group in the second quarter valued at approximately $69,000. Russell Investments Group Ltd. grew its stake in Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company's stock valued at $33,000 after acquiring an additional 7,569 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Replimune Group by 2,020.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company's stock worth $90,000 after acquiring an additional 9,235 shares during the period. 92.53% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on REPL shares. Piper Sandler upgraded Replimune Group from a "neutral" rating to an "overweight" rating and set a $13.00 price target on the stock in a research report on Monday, October 20th. Leerink Partners upgraded shares of Replimune Group from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $3.00 to $13.00 in a research report on Monday, October 20th. Leerink Partnrs upgraded Replimune Group from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 20th. JPMorgan Chase & Co. upgraded shares of Replimune Group from an "underweight" rating to a "neutral" rating and set a $11.00 price target for the company in a report on Monday, October 20th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Replimune Group in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $9.75.
Get Our Latest Report on Replimune Group
About Replimune Group
(
Get Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
